ACHV - Achieve Life Sciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.85
+0.36 (+14.46%)
As of 1:07PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.49
Open2.59
Bid2.88 x 1200
Ask2.88 x 1100
Day's Range2.51 - 3.10
52 Week Range2.40 - 38.50
Volume404,610
Avg. Volume928,617
Market Cap12.97M
Beta2.74
PE Ratio (TTM)N/A
EPS (TTM)-13.66
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • Achieve Announces Positive Cytisine Data Published in International Journal of Drug Policy
    PR Newswire6 days ago

    Achieve Announces Positive Cytisine Data Published in International Journal of Drug Policy

    The observational study compared the effectiveness of cytisine and nicotine replacement therapy (NRT) as an aid to smoking cessation in the Russian Federation. Evaluation of 301 subjects who had used either cytisine or NRT determined that smokers in the cytisine group were approximately three times more likely to achieve 90-days abstinence compared to those who attempted to quit with NRT (p=0.011).

  • Achieve Life Sciences Announces Cytisine Data Presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Conference
    PR Newswire18 days ago

    Achieve Life Sciences Announces Cytisine Data Presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Conference

    The presentations include a review of cytisine's safety profile and an overview of Achieve's upcoming Phase 2b study, planned to initiate later this year. "This conference provides an excellent opportunity to update the scientific community on the progress we continue to make in advancing the global availability of cytisine," commented Dr. Cindy Jacobs, MD, PhD, Chief Medical Officer of Achieve. Two, investigator-sponsored Phase 3 clinical trials of cytisine were successfully completed in over 2,000 patients.

  • Achieve to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 6, 2018
    PR Newswire19 days ago

    Achieve to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 6, 2018

    SEATTLE and VANCOUVER, British Columbia , Sept. 5, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

  • PR Newswire2 months ago

    Achieve Reports Financial Results for Second Quarter 2018 and Provides Cytisine Clinical Development Update

    SEATTLE and VANCOUVER, British Columbia , Aug. 8, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

  • PR Newswire2 months ago

    Achieve Life Sciences to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 8, 2018

    SEATTLE and VANCOUVER, British Columbia, Aug. 2, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it will report its second quarter 2018 financial results on Wednesday, August 8, 2018. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, clinical development program, and general corporate update. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisine.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Stocks to Watch: Achieve Life Sciences and Pfizer

    NEW YORK, NY / ACCESSWIRE / July 12, 2018 / Shares of Achieve Life Sciences exploded on Wednesday after the company announced the advancement of the Cytisine Development Program after its meeting with ...

  • Benzinga2 months ago

    Achieve Life Sciences Shares Surge On Development Plan For Smoking Cessation Candidate

    Achieve Life Sciences Inc (NASDAQ: ACHV) shares are skyrocketing as the clinical-stage biotech moves one step closer to filing a New Drug Application for its smoking cessation pipeline candidate cytisine. The company said it will conduct a Phase 2b optimization trial in about 250 smokers in the U.S., with various dosing schedules to determine efficacy, safety and compliance profiles.

  • PR Newswire2 months ago

    Achieve Life Sciences Announces Advancement of Cytisine Development Program Following Meeting with the FDA

    SEATTLE and VANCOUVER, British Columbia, July 11, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced an update on the cytisine development program following a meeting conducted with the United States (U.S.) Food and Drug Administration (FDA). The meeting with the FDA on the non-clinical and clinical development plans has further defined Achieve's Phase 3 clinical program and expected future New Drug Application (NDA) submission. Based on the FDA's recommendations to further characterize cytisine dosing prior to NDA submission, Achieve plans to conduct a Phase 2b optimization trial in approximately 250 smokers in the U.S., with various cytisine dosing schedules to evaluate overall treatment efficacy, safety, and compliance profiles for cytisine.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Puma Biotechnology and Achieve Life Sciences

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Biotech stocks Puma Biotechnology and Achieve Life Sciences soared in Tuesday's trading session after each company had positive developments. Puma rose after ...

  • Benzinga3 months ago

    Achieve Life Sciences Shares Rip Higher On Positive Data For Smoking Cessation Drug

    Achieve Life Sciences Inc (NASDAQ: ACHV ) shares were posting double-digit gains Tuesday on roughly 83 times the stock's average volume. The stock was up 31 percent at the time of publication at $4.97. ...

  • PR Newswire3 months ago

    Achieve Announces Positive Cytisine Data Demonstrating No Clinically Significant Drug-Drug Interaction

    The study demonstrated that cytisine has no clinically significant interaction with any of the hepatic enzymes commonly responsible for drug metabolism nor clinically significant interaction with drug transporters. This suggests that cytisine may be administered with other medications without the need to modify the dose of the co-administered drug. Dr. Anthony Clarke, Chief Scientific Officer of Achieve commented: "We are very pleased with the results of these detailed studies.

  • PR Newswire3 months ago

    Achieve Life Sciences, Inc. Announces Closing of a $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

    SEATTLE and VANCOUVER, British Columbia, June 19, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering was comprised of Class A Units, priced at a public offering price of $4.00 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock with an exercise price of $4.00 per share, and Class B Units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of Series A preferred stock, which is convertible into 250 shares of common stock, and a five-year warrant to purchase 250 shares of common stock, also with an exercise price of $4.00 per share.

  • PR Newswire3 months ago

    Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering

    SEATTLE and VANCOUVER, British Columbia, June 15, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering is comprised of Class A units, priced at a public offering price of $4.00 per unit, with each unit consisting of one share of common stock and a five-year warrant to purchase one share of common stock with an exercise price of $4.00 per share, and Class B units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of Series A preferred stock, which is convertible into 250 shares of common stock, and a five-year warrant to purchase 250 shares of common stock, also with an exercise price of $4.00 per share.

  • PR Newswire3 months ago

    Achieve Announces Publication of Cytisine Data for Next-Generation Cytisine Molecules

    The University of Bristol strategic collaboration uses a combination of computational docking and chemical synthesis to design and generate precision chemical keys for important biological locks. Nicotinic acetylcholine receptors (nAChR) associated with acetylcholine-mediated neurotransmission have been linked to several neurological conditions and public health issues, notably tobacco addiction.

  • Should You Be Concerned About Achieve Life Sciences Inc’s (NASDAQ:ACHV) Shareholders?
    Simply Wall St.4 months ago

    Should You Be Concerned About Achieve Life Sciences Inc’s (NASDAQ:ACHV) Shareholders?

    In this article, I will take a quick look at Achieve Life Sciences Inc’s (NASDAQ:ACHV) recent ownership structure – an unconventional investing subject, but an important one. Ownership structure ofRead More...

  • Achieve Life Sciences, Inc. Announces Reverse Stock Split
    PR Newswire4 months ago

    Achieve Life Sciences, Inc. Announces Reverse Stock Split

    SEATTLE and VANCOUVER, British Columbia, May 23, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective on May 23, 2018, and shares will begin trading on the split-adjusted basis on the Nasdaq Capital Market under the Company's existing trading symbol "ACHV" at market open on May 24, 2018. The new CUSIP number following the reverse stock split will be 004468203.

  • Achieve Reports Financial Results for First Quarter 2018
    PR Newswire5 months ago

    Achieve Reports Financial Results for First Quarter 2018

    SEATTLE and VANCOUVER, British Columbia , May 9, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

  • Achieve Announces Patent Granted on Novel Formulation of Cytisine
    PR Newswire5 months ago

    Achieve Announces Patent Granted on Novel Formulation of Cytisine

    SEATTLE and VANCOUVER, British Columbia, May 7, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that the UK Intellectual Property Office has granted Achieve a patent (no. 2550241) on cytisine succinate salt. Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisine.

  • Achieve Life Sciences Announces Cytisine Symposium at the 17th World Conference on Tobacco or Health
    PR Newswire7 months ago

    Achieve Life Sciences Announces Cytisine Symposium at the 17th World Conference on Tobacco or Health

    BOTHELL, Wash. and VANCOUVER, British Columbia, March 6, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), today announced that the World Conference on Tobacco or Health (WCTOH) will be holding a symposium on cytisine research at this year's annual conference, March 7-9th in Cape Town, South Africa. The cytisine symposium titled "Is a Globally Affordable Medication to Treat Tobacco Dependence Achievable? The Case of Cytisine." will be held on Friday, March 9th at 7:45am.

  • Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results
    CNW Group7 months ago

    Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results

    Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results

  • Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results
    PR Newswire7 months ago

    Achieve Announces Recent Highlights and Reports Year-End 2017 Financial Results

    BOTHELL, Wash. and VANCOUVER, British Columbia , March 1, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and ...

  • Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
    CNW Group7 months ago

    Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study

    Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study

  • Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study
    PR Newswire7 months ago

    Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study

    The study, initiated in October 2017, evaluated the repeat-dose PK and PD effects of 1.5mg and 3mg cytisine in 24 healthy volunteer smokers aged 18-65 years when administered over the standard 25-day course of treatment. The PK results indicated expected increases in plasma concentration between the standard and higher doses of cytisine with no evidence of drug accumulation. Cytisine was well-tolerated and reported adverse events were mostly mild and short-lived.

  • Innovative Cancer Immunotherapy Company, Novelogics Biotechnology, Inc. adds Scott D. Cormack to the Board of Directors to Expand Strategic Growth Plans
    CNW Group7 months ago

    Innovative Cancer Immunotherapy Company, Novelogics Biotechnology, Inc. adds Scott D. Cormack to the Board of Directors to Expand Strategic Growth Plans

    Innovative Cancer Immunotherapy Company, Novelogics Biotechnology, Inc. adds Scott D. Cormack to the Board of Directors to Expand Strategic Growth Plans

  • Benzinga8 months ago

    A Day Trader's View On Why Bigger Is (Usually) Better

    You may remember that I’ve been using 2018 as a year to experiment with t rading through an IRA account . It’s been a challenge so far, with only a starting balance of just over $8,000. But I was ready ...